- Home
- DMAC
DMAC
DiaMedica Therapeutics Inc.
as 04-01-2025 10:35am EST
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | MINNEAPOLIS |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $8.00 | AVG Volume (30 days): | 86.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.14 - $6.82 | Next Earning Date: | 03-17-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest DiaMedica Therapeutics Inc. News
DMAC Breaking Stock News: Dive into DMAC Ticker-Specific Updates for Smart Investing
GuruFocus.com
13 days ago
DiaMedica Therapeutics Inc (DMAC) Q4 2024 Earnings Call Highlights: Strong Financial Position ...
Thomson Reuters StreetEvents
14 days ago
Q4 2024 DiaMedica Therapeutics Inc Earnings Call
Business Wire
15 days ago
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results
Simply Wall St.
15 days ago
Insider Stock Buying Reaches US$9.00m On DiaMedica Therapeutics
Business Wire
21 days ago
DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025
Business Wire
a month ago
DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors
Business Wire
a month ago
DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
Business Wire
2 months ago
DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Compare DMAC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DMAC DiaMedica Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.